ArticleDiscover oncology2025
Single-cell transcriptomic profiling and machine learning identify S-nitrosylation-associated LAMC2 as a key prognostic driver in pancreatic cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Peripheral blood biomarkers in PD-1/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPancreatic cancer (PC) remains one of the deadliest malignancies worldwide, characterized by late diagnosis, limited therapeutic options, and dismal prognosis. Post-translational modifications (PTMs) are increasingly recognized as key regulators of tumor biology, yet the role of S-nitrosylation-a redox-based cysteine modification-has not been systematically investigated in PC.
methodsWe integrated bulk and single-cell transcriptomic data from TCGA, ICGC, and GEO cohorts to comprehensively profile S-nitrosylation-related gene expression. A large-scale machine-learning framework incorporating 101 algorithmic combinations was used to construct an optimized prognostic model. Kaplan-Meier, ROC, and PCA analyses evaluated predictive power and stability across nine independent cohorts. The key hub gene LAMC2 was identified and subjected to single-gene bioinformatic analysis and functional validation through in-vitro experiments using MIA-PaCa-2 cells.
resultsS-nitrosylation exhibited the highest enrichment among all PTM types in pancreatic cancer and was mainly localized to malignant ductal and fibroblast cells. The StepCox(backward) + GBM model showed excellent prognostic performance (TCGA C-index = 0.827) and successfully stratified patients into high- and low-risk groups across multiple external datasets. High-risk patients displayed distinct transcriptional profiles and significantly worse survival outcomes (all p < 0.01). Among S-nitrosylation-related genes, LAMC2 showed the strongest correlation with risk score (r = 0.63) and was consistently upregulated in tumors. Cox and GSEA analyses linked LAMC2 to epithelial-mesenchymal transition, TGF-β, and hypoxia pathways. Functionally, LAMC2 knockdown suppressed migration and colony formation in pancreatic cancer cells.
conclusionsThis study establishes S-nitrosylation as a crucial PTM in pancreatic cancer and introduces a robust machine-learning-based prognostic model. LAMC2 is identified as a key oncogenic effector connecting S-nitrosylation dysregulation to tumor aggressiveness, providing novel prognostic and therapeutic insights for pancreatic cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.